Clinical trials on insomnia and Parkinson’s Disease | ||
Name of paper | Author(s) | Journal/Issue |
Efficacy and safety of SQJZ herbal mixtures on nonmotor symptoms in Parkinson disease patients: Protocol for a randomized, double-blind, placebo-controlled trial | Shi J, Tian J, Li T, Qin B, Fan D, Ni J, Wei M et al. | Medicine (Baltimore) 2017, 96(50): e8824 |
Efficacy of Yokukansankachimpihange on sleep disturbance in Parkinson’s disease: A study protocol of a randomized, double blind, placebo-controlled pilot trial | Jang JH, Lee J, Jung I, Yoo H | Medicine (Baltimore) 2018, 97(26): e11298 |
Opicapone as an adjunct to levodopa in patients with Parkinson’s disease and end-of-dose motor fluctuations: a randomized, double-blind, controlled trial | Ferreira JJ, Lees A, Rocha JF, Poewe W, Rascol O, Soares-da-Silva P | Lancet Neurology 2016, 15(2): 154-165 |
Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson’s disease (EASE LID 3) | Oertel W, Eggert K, Pahwa R, Tanner CM, Hauser RA, Trenkwalder C, Ehret R et al. | Movement Disorders 2017, 32(12): 1701-1709 |
Real-world pharmacological treatment patterns of patients with young-onset Parkinson’s disease in Japan: a medical claims database analysis | Kasamo S, Takeuchi M, Ikuno M, Kawasaki Y, Tanaka S, Takahashi R, Kawakami K | Journal of Neurology 2019, 266: 1944-1952 |
Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre study | Postuma RB, Iranzo A, Hu M, Högl B, Boeve BF, Manni R, Oertel WH et al. | Brain. 2019, 142(3): 744-759 |